Sanara MedTech is a small U.S. medical technology company that sells disposable, single-use soft tissue repair and bone fusion products to surgeons in hospitals and ASCs. Its two core products drive the vast majority of revenue: CellerateRX Surgical, a hydrolyzed collagen powder applied to surgical wounds to support healing — particularly in high-risk patients with obesity, diabetes, or hypertension — and BIASURGE, a sterile antimicrobial irrigation solution designed as a direct substitute for traditional saline. Sanara also sells a smaller portfolio of bone fusion products used in spinal and orthopedic procedures. Products are sold exclusively in the U.S. through roughly 40 in-house field reps who manage a network of over 400 independent regional distributors. Revenue is generated on a per-procedure basis, with hospitals absorbing product costs as part of bundled DRG reimbursement — meaning Sanara faces no direct payer reimbursement risk. Instead, the sales pitch is health economic: CellerateRX is argued to reduce costly readmissions and revision procedures, justifying its cost to hospital procurement teams. Gross margins run around 92-93%, reflecting the disposable product model and use of contract manufacturers. Growth is driven by converting approved-but-inactive facilities into active customers, deepening surgeon penetration within existing facilities, and expanding into new surgical specialties beyond spine and orthopedics. Sanara recently discontinued its Tissue Health Plus wound care platform and is developing OsStic BioAdhesive, an injectable bone void filler with FDA Breakthrough Device designation, targeting a commercial launch in Q1 2027.